MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

137.84
+3.55
+2.64%
After Hours: 137.84 0 0.00% 16:00 07/14 EDT
OPEN
133.61
PREV CLOSE
134.29
HIGH
138.33
LOW
131.02
VOLUME
384.42K
TURNOVER
--
52 WEEK HIGH
158.93
52 WEEK LOW
90.06
MARKET CAP
6.61B
P/E (TTM)
-26.3280
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ASND stock price target is 181.12 with a high estimate of 209.16 and a low estimate of 154.86.

EPS

ASND News

More
Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ?
Insider Monkey · 3d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 6d ago
Ascendis Pharma Prices 4.2M ADS Public Offering @$142/ADS
Ascendis Pharma A/S (NASDAQ: ASND) announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares ("ADSs"), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS. All of
Benzinga · 6d ago
Thomas M. Soloway on Satsuma Pharma's board
Satsuma Pharmaceuticals (STSA -0.3%) appointed industry veteran Thomas M. Soloway, currently serving as EVP and COO of Audentes Therapeutics (BOLD), to its
seekingalpha · 6d ago
Ascendis Pharma initiates capital raise
Ascendis Pharma (ASND +1.5%) commences an underwritten public offering of $500M of American Depositary Shares (ADSs) with 30-day underwriters option to pur
seekingalpha · 07/06 22:08
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
GlobeNewswire · 07/06 17:58
Ascendis Pharma Reports Commenced $500M ADS Offering
Benzinga · 07/06 17:07
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan
GlobeNewswire · 07/06 14:25

Industry

Biotechnology & Medical Research
+2.53%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About ASND

ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
More

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASND stock methods without spending real money on the virtual paper trading platform.